Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

被引：0
|
作者：
Antoinette MaassenVanDenBrink
Gisela M. Terwindt
Joshua M. Cohen
Steve Barash
Verena Ramirez Campos
Maja Galic
Xiaoping Ning
Mikko Kärppä
机构：
[1] Erasmus University Medical Center Rotterdam,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[2] Leiden University Medical Center,Department of Neurology
[3] Teva Pharmaceutical Products R&D,Research Unit of Clinical Neuroscience
[4] Inc.,undefined
[5] Teva Pharmaceuticals Europe B.V.,undefined
[6] University of Oulu and Medical Research Center,undefined
[7] Oulu University Hospital,undefined
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Age; Sex; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 47 条
  • [21] Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine:: results of a phase III, multicentre, placebo-controlled study across three attacks
    Stark, R
    Dahlöf, C
    Haughie, S
    Hettiarachchi, J
    CEPHALALGIA, 2002, 22 (01) : 23 - 32
  • [22] Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials
    Matsumori, Yasuhiko
    Ishida, Miki
    Iba, Katsuhiro
    Kim, Byung-Kun
    Ning, Xiaoping
    Nakai, Masami
    Koga, Nobuyuki
    HEADACHE, 2023, 63 (09): : 1304 - 1313
  • [23] Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies
    Ashina, Messoud
    Vasudeva, Raghavendra
    Jin, Leah
    Lombard, Louise
    Gray, Elizabeth
    Doty, Erin G.
    Yunes-Medina, Laura
    Kinchen, Kraig S.
    Tassorelli, Cristina
    HEADACHE, 2019, 59 (10): : 1788 - 1801
  • [24] Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
    Dodick, David W.
    Goadsby, Peter J.
    Lucas, Christian
    Jensen, Rigmor
    Bardos, Jennifer N.
    Martinez, James M.
    Zhou, Chunmei
    Aurora, Sheena K.
    Yang, Jyun Yan
    Conley, Robert R.
    Oakes, Tina
    CEPHALALGIA, 2020, 40 (09) : 935 - 948
  • [25] Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study
    Carpay, J
    Schoenen, J
    Ahmad, F
    Kinrade, F
    Boswell, D
    CLINICAL THERAPEUTICS, 2004, 26 (02) : 214 - 223
  • [26] Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks. A randomized, double-blind, placebo-controlled study
    Tfelt-Hansen, P
    Bach, F
    Daugaard, D
    Tsiropoulos, I
    Riddersholm, B
    CEPHALALGIA, 2005, 25 (10) : 932 - 932
  • [27] Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
    Stauffer, Virginia L.
    Turner, Ira
    Kemmer, Phebe
    Kielbasa, William
    Day, Kathleen
    Port, Martha
    Quinlan, Tonya
    Camporeale, Angelo
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [28] Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
    Virginia L. Stauffer
    Ira Turner
    Phebe Kemmer
    William Kielbasa
    Kathleen Day
    Martha Port
    Tonya Quinlan
    Angelo Camporeale
    The Journal of Headache and Pain, 2020, 21
  • [29] Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)
    Tobin, Joshua A.
    Joshi, Shivang
    Ford, Janet H.
    Nichols, Russell M.
    Foster, Shonda A.
    Ruff, Dustin
    Detke, Holland C.
    Aurora, Sheena K.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1030 - 1038
  • [30] Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
    Andrews, J. Scott
    Kudrow, David
    Rettiganti, Mallikarjuna
    Oakes, Tina
    Bardos, Jennifer N.
    Wenzel, Richard
    Kuruppu, Dulanji K.
    Gaul, Charly
    Martinez, James M.
    JOURNAL OF PAIN RESEARCH, 2021, 14 : 2059 - 2070
12345